INCB054707 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

Nov 4, 2021 → Feb 28, 2024

NCT ID

NCT05061693

About INCB054707 + Placebo

INCB054707 + Placebo is a phase 2 stage product being developed by Incyte for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT05061693. Target conditions include Prurigo Nodularis.

What happened to similar drugs?

1 of 7 similar drugs in Prurigo Nodularis were approved

Approved (1) Terminated (0) Active (6)

✅UpadacitinibAbbVieApproved

🔄Rocatinlimab + PlaceboAmgenPhase 3

🔄DupilumabSanofiPhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

🔄Povorcitinib + PlaceboIncytePhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05061693	Phase 2	Completed	Nov 4, 2021	Feb 28, 2024	Prurigo Nodularis
NCT05068466	Phase 1	Completed	Oct 21, 2021	Jan 25, 2022	Healthy Participants
NCT04818346	Phase 2	Completed	May 6, 2021	May 24, 2023	NonSegmental Vitiligo
NCT04476043	Phase 2	Completed	Aug 25, 2020	Aug 16, 2023	Hidradenitis Suppurativa
NCT03607487	Phase 2	Completed	Oct 15, 2018	Aug 13, 2019	Hidradenitis Suppurativa

Competing Products

20 competing products in Prurigo Nodularis

See all competitors

Product	Company	Stage	Hype Score
Vixarelimab + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
Upadacitinib	AbbVie	Approved	50
Pimecrolimus + Hydrocortisone + Pimecrolimus	Novartis	Phase 2	35
Rocatinlimab + Placebo	Amgen	Phase 3	44
Abrocitinib	Pfizer	Phase 2	35
Dupilumab SAR231893 (REGN668)	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Phase 3	47
Dupilumab	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Pre-clinical	30
Ruxolitinib Cream 1.5%	Incyte	Phase 1	26
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
Povorcitinib + Placebo	Incyte	Phase 3	44
Povorcitinib + Placebo	Incyte	Phase 3	44
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
CDX-0159 + Normal saline	Celldex Therapeutics	Phase 1	23
barzolvolimab	Celldex Therapeutics	Phase 2	33
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	32
Nalbuphine ER Tablets + Placebo Tablets	Trevi Therapeutics	Phase 2/3	32
serlopitant + Placebo	Vyne Therapeutics	Phase 2	25